Perioperative Therapy for Resectable Pancreatic Cancer

• Status: Completed
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This phase II trial studies how well giving combination chemotherapy together with intensity-modulated radiation therapy (IMRT) and surgery works in treating patients with localized pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, docetaxel, capecitabine, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy, such as IMRT, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving more than one drug (combination chemotherapy) together with intensity-modulated radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Washington
• Collaborator: National Cancer Institute (NCI)
• Treatments: Capecitabine; Docetaxel; Gemcitabine; Oxaliplatin

Criteria

Inclusion Criteria:

• Patients must have histologically or cytologically confirmed diagnosis of localized, resectable or borderline resectable, pancreatic adenocarcinoma T1-T3, N0-N1, M0; stage is determined by helical multi-phase computed tomography (CT) and/or endoscopic ultrasound according to published guidelines; resectability is determined by the treating surgeon and published guidelines (National Comprehensive Cancer Network)

• Resectable Disease- Head/Body/Tail of pancreas:

• No distant metastases

• Clear fat plane around celiac and superior mesenteric arteries (SMA)

• Patent superior mesenteric vein (SMV) and portal vein (PV)

• Borderline Resectable Disease -Head/Body of pancreas:

• Tumor abutment on SMA

• SMV/portal vein impingement or occlusion if involving only a short segment, with open vein both proximally and distally (if proximal vein is occluded up to the portal vein branches then disease is unresectable)

• Colon or mesocolon invasion

• Gastroduodenal artery (GDA) encasement up to origin at hepatic artery

• Tail of pancreas:

• Adrenal, colon or mesocolon, or kidney invasion

• Preoperative evidence of biopsy-positive peripancreatic lymph node

• No prior therapy for pancreatic cancer

• Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

• Leucocytes >= 3,000/uL

• Absolute Neutrophil Count >= 1,500/uL

• Platelets >= 100,000/uL

• Total Bilirubin:

• If within normal limits (WNL) to =< 2.0, the subject is eligible

• If > 2.0 - < 6.0, subject is eligible IF they have a biliary stent and total bilirubin is decreasing

• If >= 6.0, subject is not eligible

• Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvic transaminase [SGPT]) =< 2.5 X institutional upper limit of normal or =< 1.5 X upper limit of normal (ULN) if alkaline phosphatase (Alk Phos) > 2.5 X ULN or if the subject has a biliary stent and the liver function tests (LFTs) are decreasing the subject is eligible

• Creatinine clearance >= 30%

• Negative pregnancy test for women of childbearing potential; women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately

• Ability to swallow and retain oral medication

• Ability to understand and willingness to sign a written informed consent document

Exclusion Criteria:

• Patients may not be receiving any other investigational agents

• Histology other than adenocarcinoma

• Patients with permanently unresectable pancreatic adenocarcinoma as determined by the treating physician and published guidelines (National Comprehensive Cancer Network)

• Unresectable disease

• Head of pancreas:

• Distant metastases (includes celiac and/or para-aortic)

• SMA, celiac encasement

• SMV/portal occlusion

• Aortic, inferior vena cava (IVC) invasion or encasement

• Invasion of SMV below transverse mesocolon

• Body of pancreas:

• Distant metastases (includes celiac and/or para-aortic); at the discretion of the treating surgeon, body and tail lesions that have positive celiac and/or para-aortic nodes in close vicinity to the primary may be borderline rather than unresectable

• SMA, celiac, hepatic encasement

• SMV/portal extended occlusion

• Aortic invasion

• Tail of pancreas:

• Distant metastases (includes celiac and/or para-aortic)

• SMA, celiac encasement

• Rib, vertebral invasion

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, docetaxel, capecitabine, oxaliplatin or other agents used in the study

• Patients who have received prior chemotherapy or radiotherapy for the diagnosis of pancreatic cancer

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

• Inability to comply with study and/or follow-up procedures

• Pregnancy or lactation

• Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy